RxDoctor Payments Data

Frank Winton, MD

Family Medicine · Fallbrook, CANPI 1750300315

Payments from drug & device makers

$1,592in general payments, 2019–2025

Across 81 payments — averaging $19.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$438
  • GSK$240
  • Amgen$145
  • AbbVie$102
  • Pfizer$102
  • Lilly USA, LLC$93
  • plus $471 from 17 others

What the payments were for

  • Food & beverage$1,592100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,592 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$107,051
Medicare patients
321
Services billed
1,405

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$84,068
MounjaroTirzepatide33$32,749
OzempicSemaglutide24$24,549
MyrbetriqMirabegron21$15,946
JardianceEmpagliflozin13$15,812
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,674
Levemir FlexpenInsulin Detemir21$6,743
Breo ElliptaFluticasone/Vilanterol11$5,315
BelsomraSuvorexant12$5,194
SymbicortBudesonide/Formoterol Fumarate12$4,177
EdarbyclorAzilsartan Med/Chlorthalidone12$3,174
Testosterone18$2,993
Omeprazole120$2,580
Atorvastatin Calcium307$2,576
Gabapentin138$2,557

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$102$84,06884 claims
Lilly USA, LLCMounjaro$93$32,74933 claims
GSKTrelegy Ellipta, Breo Ellipta$240$16,98928 claims
Astellas Pharma US IncMyrbetriq$61$15,94621 claims
MerckBelsomra$35$5,19412 claims
AstraZenecaSymbicort$438$4,17712 claims
AbbVieSynthroid$102$91516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.

Other family medicine in Fallbrook

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →